Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28697725 | 0.91 | NOS2 (0.39) | NOS2ALDH1A1CYP3A4MAPTCYP2D6 | |
| SCHEMBL8283504 | 0.76 | EPHX1 (0.38) | ALDH1A1MEN1LMNAALOX12KMT2A | |
| SCHEMBL11316747 | 0.76 | ALDH1A1 (0.38) | NOS2ALDH1A1MEN1LMNAALOX12 | |
| SCHEMBL11316752 | 0.76 | ALDH1A1 (0.38) | NOS2ALDH1A1MEN1LMNAALOX12 | |
| SCHEMBL3064939 | 0.75 | NOS2 (0.42) | NOS2ALDH1A1MEN1LMNAALOX12 | |
| SCHEMBL20629585 | 0.75 | NOS2 (0.31) | NOS2ALDH1A1MEN1LMNAALOX12 | |
| SCHEMBL17818902 | 0.73 | EPHX1 (0.38) | ALDH1A1MEN1LMNAALOX12KMT2A | |
| SCHEMBL17608724 | 0.71 | MEN1 (0.34) | NOS2ALDH1A1MEN1LMNAALOX12 | |
| SCHEMBL3983126 | 0.71 | MEN1 (0.37) | NOS2ALDH1A1MEN1LMNAALOX12 | |
| SCHEMBL1876976 | 0.68 | EPHX1 (0.39) | ALDH1A1SMN1; SMN2CYP3A4MAPTEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046163-A1 | FURANOPYRIMIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-02-24 | — | — | US | disclosed |
| US-20110046163-A1 | FURANOPYRIMIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-02-24 | — | — | US | disclosed |
| WO-2011022694-A2 | FURANOPYRIMIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011022694-A2 | FURANOPYRIMIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046163-A1 | FURANOPYRIMIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE | CNR1, CNR2, GPR17 | NOS2 4420/4885ALDH1A1 1206/4885MEN1 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.